ELVN Q1 2024 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$26M

Net Income

-$23M

EPS (Diluted)

$-0.54

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$343M

Total Liabilities

$25M

Stockholders' Equity

$318M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$26M	-$16M	-58.3%
Net Income	-$23M	-$15M	-54.4%